Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics

Sangamo Therapeutics, Inc. (SGMO): $4.14

0.05 (+1.22%)

POWR Rating

Component Grades













Add SGMO to Watchlist
Sign Up

Industry: Biotech



in industry


  • SGMO scores best on the Growth dimension, with a Growth rank ahead of 76.74% of US stocks.
  • SGMO's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • SGMO's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

SGMO Stock Summary

  • Of note is the ratio of Sangamo Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.76% of US stocks have a lower such ratio.
  • For SGMO, its debt to operating expenses ratio is greater than that reported by merely 17.34% of US equities we're observing.
  • As for revenue growth, note that SGMO's revenue has grown -6.34% over the past 12 months; that beats the revenue growth of only 12.69% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Sangamo Therapeutics Inc, a group of peers worth examining would be NRIX, CNCE, XENE, BPMC, and XBIT.
  • SGMO's SEC filings can be seen here. And to visit Sangamo Therapeutics Inc's official web site, go to

SGMO Valuation Summary

  • In comparison to the median Healthcare stock, SGMO's price/earnings ratio is 129.04% lower, now standing at -10.6.
  • Over the past 243 months, SGMO's price/sales ratio has gone down 42.3.
  • SGMO's price/sales ratio has moved down 42.3 over the prior 243 months.

Below are key valuation metrics over time for SGMO.

Stock Date P/S P/B P/E EV/EBIT
SGMO 2021-08-31 10.5 3.2 -10.6 -9.7
SGMO 2021-08-30 10.4 3.2 -10.6 -9.7
SGMO 2021-08-27 10.5 3.3 -10.7 -9.8
SGMO 2021-08-26 10.2 3.2 -10.4 -9.4
SGMO 2021-08-25 10.4 3.2 -10.6 -9.7
SGMO 2021-08-24 10.4 3.2 -10.5 -9.6

SGMO Growth Metrics

    Its 5 year revenue growth rate is now at 258.23%.
  • Its 4 year net income to common stockholders growth rate is now at -84.95%.
  • Its 3 year revenue growth rate is now at 166.38%.
SGMO's revenue has moved up $30,815,000 over the prior 34 months.

The table below shows SGMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 110.701 -233.251 -178.286
2021-09-30 108.515 -184.832 -181.394
2021-06-30 137.715 -92.345 -135.256
2021-03-31 131.396 120.215 -124.016
2020-12-31 118.192 169.875 -120.996
2020-09-30 147.243 153.354 -75.837

SGMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SGMO has a Quality Grade of C, ranking ahead of 46.27% of graded US stocks.
  • SGMO's asset turnover comes in at 0.127 -- ranking 244th of 682 Pharmaceutical Products stocks.
  • ALBO, LXRX, and ATNX are the stocks whose asset turnover ratios are most correlated with SGMO.

The table below shows SGMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.127 1 -0.356
2021-06-30 0.152 1 -0.251
2021-03-31 0.143 1 -0.252
2020-12-31 0.140 1 -0.270
2020-09-30 0.191 1 -0.186
2020-06-30 0.162 1 -0.272

SGMO Price Target

For more insight on analysts targets of SGMO, see our SGMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.67 Average Broker Recommendation 1.55 (Moderate Buy)

SGMO Stock Price Chart Interactive Chart >

Price chart for SGMO

SGMO Price/Volume Stats

Current price $4.14 52-week high $12.45
Prev. close $4.09 52-week low $3.12
Day low $4.01 Volume 1,627,600
Day high $4.14 Avg. volume 1,548,622
50-day MA $4.02 Dividend yield N/A
200-day MA $6.55 Market Cap 607.28M

Sangamo Therapeutics, Inc. (SGMO) Company Bio

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.

SGMO Latest News Stream

Event/Time News Detail
Loading, please wait...

SGMO Latest Social Stream

Loading social stream, please wait...

View Full SGMO Social Stream

Latest SGMO News From Around the Web

Below are the latest news stories about Sangamo Therapeutics Inc that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

Sangamo Therapeutics rises 5% after hours following Q4 earnings

Sangamo Therapeutics' (NASDAQ:SGMO) Q4 2021 beats on the top and bottom lines has propelled the stock 5% higher in after-hours trading. The company's net loss in the quarter narrowed ~8% to ~$37.5M. Basic and diluted net loss per share was -$0.26, compared to -$0.29 in Q4 2020. Revenue increased ~8%...

Seeking Alpha | February 24, 2022

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

BRISBANE, Calif., February 24, 2022--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.

Yahoo | February 24, 2022

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

BRISBANE, Calif., February 17, 2022--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide

Yahoo | February 17, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO) and Applied Genetic Technologies (AGTC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (SGMO – Research Report) and Applied Genetic Technologies (AGTC – Research Report). Sangamo Biosciences (SGMO) In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences, with a price target of $10.00. The company's shares closed last Tuesday at $5.61, close to its 52-week low of $5.32. According to TipRanks.

Catie Powers on TipRanks | February 8, 2022

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although

Yahoo | February 8, 2022

Read More 'SGMO' Stories Here

SGMO Price Returns

1-mo 13.42%
3-mo -31.51%
6-mo -44.80%
1-year -65.41%
3-year -60.91%
5-year -52.95%
YTD -44.80%
2021 -51.94%
2020 86.44%
2019 -27.09%
2018 -30.00%
2017 437.70%

Continue Researching SGMO

Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:

Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.3045 seconds.